Health

Tirzepatide noninferior to dulaglutide for CV outcomes in type 2 diabetes

TribeNews
By TribeNews 15 Views Add a Comment
0 Min Read
Tirzepatide noninferior to dulaglutide for CV outcomes in type 2 diabetes

Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic CV disease, according to a study published in the Dec. 18/25 issue of the New England Journal of Medicine…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app